Motivators for participation in a whole-genome sequencing study: Implications for translational genomics research

European Journal of Human Genetics

Volumn 19, Issue 12, 2011, Pages 1213-1217

  Facio, Flavia M ^a   Brooks, Stephanie ^a,b   Loewenstein, Johanna ^a,c   Green, Susannah ^a,d   Biesecker, Leslie G ^a   Biesecker, Barbara B ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b SARAH LAWRENCE COLLEGE   (United States)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d KENYON COLLEGE   (United States)

Author keywords

early adopters; personalized medicine; whole genome sequencing

Indexed keywords

ADULT; ALTRUISM; ARTICLE; FEMALE; GENE SEQUENCE; GENOMICS; HEALTH HAZARD; HUMAN; MALE; MOTIVATION; PRIORITY JOURNAL; TRANSLATIONAL RESEARCH;

ADULT; AGED; ALTRUISM; FEMALE; GENOME, HUMAN; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDIVIDUALIZED MEDICINE; INTENTION; MALE; MIDDLE AGED; QUESTIONNAIRES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 81555203460     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2011.123     Document Type: Article

References (31)

1. Morton NE: The detection and estimation of linkage between the genes for elliptocytosis and the Rh blood type. Am J Hum Genet 1956; 8: 80-96.
2. Morton NE: The mutational load due to detrimental genes in man. Am J Hum Genet 1960; 12: 348-364.
3. Charron P, Arad M, Arbustini E et al: Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2010; 31: 2715-2726.
4. Adams PC, Reboussin DM, Barton JC et al: Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med 2005; 352: 1769-1778.
5. Murphy J, Scott J, Kaufman D, Geller G, LeRoy L, Hudson K: Public perspectives on informed consent for biobanking. Am J Public Health 2009; 99: 2128-2134.
6. Biesecker LG, Mullikin JC, Facio FM et al: The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. Genome Res 2009; 19: 1665-1674.
7. van Gelderen CE, Savelkoul TJ, van Dokkum W, Meulenbelt J: Motives and perception of healthy volunteers who participate in experiments. Eur J Clin Pharmacol 1993; 45: 15-21.
8. Almeida L, Azevedo B, Nunes T, Vaz-da-Silva M, Soares-da-Silva P: Why healthy subjects volunteer for phase I studies and how they perceive their participation? Eur J Clin Pharmacol 2007; 63: 1085-1094.
9. McCarty CA, Nair A, Austin DM, Giampietro PF: Informed consent and subject motivation to participate in a large, population-based genomics study: The Marshfield Clinic Personalized Medicine Research Project. Community Genet 2007; 10: 2-9.
10. Treloar SA, Morley KI, Taylor SD, Hall WD: Why do they do it? A pilot study towards understanding participant motivation and experience in a large genetic epidemiological study of endometriosis. Community Genet 2007; 10: 61-71.
11. Nurgat ZA, Craig W, Campbell NC, Bissett JD, Cassidy J, Nicolson MC: Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer 2005; 92: 1001-1005.
12. Schutta KM, Burnett CB: Factors that influence a patient's decision to participate in a phase I cancer clinical trial. Oncol Nurs Forum 2000; 27: 1435-1438.
13. Moore S: A need to try everything: patient participation in phase I trials. J Adv Nurs 2001; 33: 738-747.
14. Henderson GE, Easter MM, Zimmer C et al: Therapeutic misconception in early phase gene transfer trials. Soc Sci Med 2006; 62: 239-253.
15. Sulmasy DP, Astrow AB, He MK et al: The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer 2010; 116: 3702-3711.
16. Gelijns A: Lessons for genomics from other technologies; in: Diffusion and use of Genomic Innovations in Health and Medicine: Workshop Summary. Washington, DC: National Academies Press, 2008, p 17.
17. Rogers EM: Diffusion of Innovations, 5th eds New York: Free Press, 2003.
18. Ashley EA, Butte AJ, Wheeler MT et al: Clinical assessment incorporating a personal genome. Lancet 2010; 375: 1525-1535.
19. Armstrong K, Weiner J, Weber B, Asch DA: Early adoption of BRCA1/2 testing: who and why. Genet Med 2003; 5: 92-98.
20. Hobbs P, Smith A, George WD, Sellwood RA: Acceptors and rejectors of an invitation to undergo breast screening compared with those who referred themselves. J Epidemiol Community Health 1980; 34: 19-22.
21. Manne SL, Chung DC, Weinberg DS et al: Knowledge and attitudes about microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. Cancer Epidemiol Biomarkers Prev 2007; 16: 2110-2117.
22. Esplen MJ, Madlensky L, Aronson M et al: Colorectal cancer survivors undergoing genetic testing for hereditary non-polyposis colorectal cancer: motivational factors and psychosocial functioning. Clin Genet 2007; 72: 394-401.
23. Sankar P, Wolpe PR, Jones NL, Cho M: How do women decide? Accepting or declining BRCA1/2 testing in a nationwide clinical sample in the United States. Community Genet 2006; 9: 78-86.
24. Balmana J, Stoffel EM, Emmons KM, Garber JE, Syngal S: Comparison of motivations and concerns for genetic testing in hereditary colorectal and breast cancer syndromes. J Med Genet 2004; 41: e44.
25. Gooding HC, Linnenbringer EL, Burack J, Roberts JS, Green RC, Biesecker BB: Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Patient Educ Couns 2006; 64: 259-267.
26. Claes E, Denayer L, Evers-Kiebooms G, Boogaerts A, Legius E: Predictive testing for hereditary non-polyposis colorectal cancer: motivation, illness representa tions and short-term psychological impact. Patient Educ Couns 2004; 55: 265-274.
27. Hurley AC, Harvey FR, Roberts JS et al: Genetic susceptibility for Alzheimer's disease: why did adult offspring seek testing? Am J Alzheimers Dis Other Demen 2005; 20: 374-381.
28. Esplen MJ, Madlensky L, Butler K et al: Motivations and psychosocial impact of genetic testing for HNPCC. Am J Med Genet 2001; 103: 9-15.
29. Roberts JS, LaRusse SA, Katzen H et al: Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord 2003; 17: 86-93.
30. Fraser L, Bramald S, Chapman C et al: What motivates interest in attending a familial cancer genetics clinic? Fam Cancer 2003; 2: 159-168.
31. Ormond KE, Wheeler MT, Hudgins L et al: Challenges in the clinical application of whole-genome sequencing. Lancet 2010; 375: 1749-1751.